Tucked away in the quiet English countryside on more than 47 acres, GW Pharmaceuticals is doing something no other drug company can do: produce the only cannabis-based medication ever approved by the US Food and Drug Administration.
That drug, a treatment for two rare types of epilepsy, inspired researchers to consider what other conditions cannabis might help. A new clinical trial at Montefiore Medical Center in New York will examine the effect of a cannabis compound called cannabidivarin, known as CBDV, on irritability and repetitive behaviors in children with autism spectrum disorder. CBDV is a non-psychoactive chemical compound and does not cause a "high."
CNN Chief Medical Correspondent Dr. Sanjay Gupta was given exclusive access to the Montefiore study and GW Pharmaceuticals, the British biopharmaceutical company that grows the cannabis used in the trials.